Advertisement
Advertisement
TOPIC

Biomedicine: Geopolitics

Related Topics:
Biomedicine: Geopolitics
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
Chinese companies now account for about half of all global biotechnology business development deals. Photo: Shutterstock
China’s private sector

China biotech firms say global push is ‘irreversible’ despite US barriers

Chinese drug makers are increasingly relying on overseas licensing deals to reach global markets amid growing geopolitical tensions.

China’s private sector

Chinese pharmaceutical firms’ cost advantages trump Pentagon blacklist: analysts

China’s private sector

Which company could become the Chinese Pfizer? Here are analysts’ top picks

US-China trade war

The next tech war? Why biotech may become a new US-China battleground

China’s biotech industry is rapidly moving up the value chain, prompting fears in the US and calls for tighter controls.

videocam
13
Chinese biotech companies have risen up the value chain in recent years, with cross-border licensing deals worth a record US$60 billion in the first quarter of 2026, according to the National Medical Products Administration. Photo: Getty Images
China’s private sector

Akeso lung cancer drug trial raises hopes in US$20b market

Ivonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy.

US-China relations

Opinion | How US tech hegemony is locking out the Global South

The world deserves better than a monopoly that builds walls and hobbles development.

videocam
4
Advertisement
Advertisement
Advertisement
China’s private sector

Chinese drug makers take on Western dominance in US$16 billion Parkinson’s race

The future of treating brain diseases could lie in non-invasive technologies, according to Chongqing Haifu Medical Technology.

Hong Kong’s Tuen Mun Hospital has for the first time in the city used a non-invasive ultrasound procedure to treat a Parkinson’s disease patient with uncontrollable tremors. Photo: Handout
China’s private sector

China’s drug makers are speeding up – will AI be their secret weapon?

Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?

Banking & finance

China healthcare stocks shine in Hong Kong amid Middle East turmoil

Hang Seng Healthcare Index outpaces broader market as Akeso, Innovent, Hansoh provide refuge for global investors.

Biomedicine: Companies

Global drug makers face pricing pressure as China targets affordable healthcare

As pharmaceutical firms navigate China’s aggressive pricing reforms, their profits could be squeezed further this year.

5
A pharmaceutical production line in Meishan, China. Photo: Costfoto/NurPhoto via Getty Images
China’s private sector

Li Ka-shing’s CK Life unit eyes China fast track for cancer vaccine pipeline

Sequencio, CK Life’s new Hong Kong unit, is advancing about 20 cancer vaccine projects as China pathway offers faster route to human trials.

In China, investigator-initiated trials allow drug makers to generate human clinical data “faster” than the conventional regulatory process. Photo: Shutterstock
Made in China 2025

Global drug giants double down on China amid push for self-reliant supply chains

Multinationals are building self-reliant supply chains in China to insulate local markets from potential trade disruptions, say analysts.

China’s private sector

US reshoring drive casts shadow over China’s contract drug makers, analyst says

Strong order backlogs underpin earnings through 2027, but analysts warn longer-term demand is less certain as US firms reshore production.

China’s private sector

Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain

US firm is strengthening its China operations amid an intensifying expansion race with other pharmaceutical giants.

The move will bring the total cumulative investment of Eli Lilly in China to nearly US$6 billion. Photo: Reuters
China trade

China supply chain expo set to welcome more US firms, launch AI section

Amid trade tensions, China Council for the Promotion of International Trade describes business communities as a ‘bridge’ for exchanges.

videocam
Robots at the Nvidia booth at the third China International Supply Chain Expo in Beijing in July 2025. Photo: Xinhua
Made in China 2025

Capital injection: China backs AI drug makers in self-reliance drive

A wave of government-linked investment is boosting Chinese AI drug makers, underscoring Beijing’s drive to build its own biotech ecosystem.

Hong Kong stock market

WuXi Biologics earnings jump as ‘follow and win the molecule’ strategy pays off

Chinese contract drug maker forecasts 46.3 per cent profit rise and signals continued growth despite US political scrutiny.

Advertisement
Advertisement
Advertisement
China’s private sector

Biomedicine | China challenges US in new drugs after industry transformation

Drug makers in China are performing cutting-edge research and licensing products to global giants after a 10-year government push supercharged the industry.

China challenges US in new drugs after industry transformation
China economy

Opinion | How a rising China is becoming a provider of global public goods

When China provides the hi-tech, low-cost hardware of development and multilateral banks provide regulatory oversight, the Global South wins.

Biomedicine: Industry Trends

China could approve first AI-designed drug next year, Merck executive says

AI and genetics are creating a ‘seismic shift’ in the pharmaceutical business, experts on Asian Financial Forum panel say.

US-China relations

Opinion | China has Trump 2.0 to thank for emerging stronger in tech and trade

As intense US-China competition becomes the new normal, pressure has strengthened China’s capacity to adapt rather than deter it from its long-term ambitions.

videocam
President Xi Jinping attends a high-level reception to ring in the Lunar New Year at the Great Hall of the People in Beijing, on January 27, 2025. Photo: Xinhua
Biomedicine: Industry Trends

Harbour BioMed stake in US drug developer shows Chinese firms’ growing clout

Latest example of Chinese drug maker acquiring equity in overseas partner shows they are becoming true development partners, analysts say.

Global drug companies no longer view Chinese firms as contract manufacturers, but as development partners, an analyst says. Photo: Shutterstock
Made in China 2025

Exclusive | China challenges US in AI drug race, but rivals still reliant on each other

While US biotech firms increase use of Chinese clinical data, Chinese firms need US counterparts for monetisation, investor and scientist says.

Science

Structural biologist Alexey Amunts launches new research lab in Shenzhen

‘Shenzhen adds another dimension; it is a place where ideas do not remain ideas for long,’ Amunts says of new position.

videocam
8
Made in China 2025

Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.

Last year, China approved 76 innovative drugs, including 47 chemical drugs and 23 biologics. Photo: Shutterstock
Banking & finance

Global firms turn to M&A in EVs and biotech to deepen China investment: KPMG

Survey of multinational corporations finds optimism in life sciences, healthcare and manufacturing, with half forecasting revenue growth.

Healthcare and life sciences are the top growth prospects over the next three to five years, according to multinational corporations. Photo: Xinhua
United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

China’s private sector

BeOne Medicines names R&D chief Wang Lai as president amid global expansion

BeOne generated global revenue of about US$3.8 billion last year, driven by its flagship products Brukinsa and Tevimbra.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement